title: Continuous infusion of local anesthesia after living donor nephrectomy: a comparative analysis.
abstract: BACKGROUND
  Today local anesthetic wound infiltration is widely recognized as a useful adjunct in a multimodality approach to postoperative pain management. The effectiveness of continuous wound infusion of ropivacaine for postoperative pain relief after laparoscopic living donor nephrectomy was analyzed in this retrospective, comparative analysis.
  
  
  METHODS
  Twenty patients undergoing living donor nephrectomy were divided into two groups: standard analgesic therapy (n=10) and ropivacaine continuous infusion group (n = 10).
  
  
  RESULTS
  We observed a significant difference in term of visual analogue scale scores, use of morphine, hospital stay, and bowel recovery in favor of the ropivacaine group. The cost analysis demonstrated an overall savings of 985 Euros/patient.
  
  
  CONCLUSIONS
  Surgical wound infusion with ropivacaine was safe and seemed to improve pain relief and accelerate recovery and discharge, reducing the overall costs of care. Postoperative pain control in the donor is of primary importance for better patient compliance and greater perceived quality of health care service.
authors.affiliation: Centre de Chirurgie Viscérale et de Transplantation-Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg-Université Louis Pasteur, Strasbourg, France.
authors.forename: F
authors.initials: F
authors.lastname: Panaro
authors.forename: F
authors.initials: F
authors.lastname: Gheza
authors.forename: T
authors.initials: T
authors.lastname: Piardi
authors.forename: M L
authors.initials: ML
authors.lastname: Woehl Jaegle
authors.forename: M
authors.initials: M
authors.lastname: Audet
authors.forename: M
authors.initials: M
authors.lastname: Cantù
authors.forename: J
authors.initials: J
authors.lastname: Cinqualbre
authors.forename: P
authors.initials: P
authors.lastname: Wolf
mesh_terms: D000577:Amides / Q000008:administration & dosage* / Q000191:economics; D000698:Analgesia / Q000191:economics / Q000379:methods*; D000779:Anesthetics, Local / Q000008:administration & dosage* / Q000191:economics; D016022:Case-Control Studies; D003362:Cost-Benefit Analysis; D003672:Defecation / Q000187:drug effects; D016527:Drug Costs; D005602:France; D017721:Hospital Costs; D006801:Humans; D036502:Infusions, Intralesional; D007558:Italy; D016030:Kidney Transplantation / Q000009:adverse effects / Q000191:economics; D010535:Laparoscopy / Q000009:adverse effects / Q000191:economics; D007902:Length of Stay; D019520:Living Donors; D009020:Morphine / Q000008:administration & dosage; D009294:Narcotics / Q000008:administration & dosage; D009392:Nephrectomy / Q000009:adverse effects / Q000191:economics; D010147:Pain Measurement; D010149:Postoperative Pain / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D020127:Recovery of Function; D012189:Retrospective Studies; D000077212:Ropivacaine; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000577:Amides; D000779:Anesthetics, Local; D009294:Narcotics; D009020:Morphine; D000077212:Ropivacaine